JAMA's policy on industry sponsored studies [1]

British Medical Journal

Volumn 332, Issue 7534, 2006, Pages 177-

  Fontanarosa, Phil B ^a   DeAngelis, Catherine D ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; DATA ANALYSIS; DRUG INDUSTRY; LETTER; MEDICAL RESEARCH; POLICY; PRIORITY JOURNAL; PUBLICATION; STATISTICAL ANALYSIS; SYSTEMATIC ERROR;

CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUG INDUSTRY; EDITORIAL POLICIES; PEER REVIEW; PERIODICALS; RESEARCH SUPPORT; UNITED STATES;

EID: 31344482076     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7534.177     Document Type: Letter

References (7)

1. Rothman KJ, Evans S. Extra scrutiny for industry funded trials. BMJ 2005;331:1350-1. (10 December.)
2. Fontanarosa FB, Flanagin A, DeAngelis CD. Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded titles. JAMA 2005;294:110-1.
3. Curfman GD, Morrisey S, Drazen JM. Expression of concern: Bombardier et al. "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.
4. N Engl J Med 2005:2813-4.
5. Hrachovec JB, Wright JM. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 2001;286:2398.
6. Gibson L. GlaxoSmithKline to publish clinical trials after US lawsuit. BMJ 2004;328:1513.
7. Maisel WH. Safety issues involving medical devices: implications of recent implantable cardioverter-defibrillator malfunctions. JAMA 2005;294:955-8.